Fig. 2 | European Journal of Nuclear Medicine and Molecular Imaging

Fig. 2

From: RADTHYR: an open-label, single-arm, prospective multicenter phase II trial of Radium-223 for the treatment of bone metastases from radioactive iodine refractory differentiated thyroid cancer

Fig. 2

Waterfall plot of total SULpeak variation at 3 months and at 6 months for each included patient according to response criteria used for 18F-FDG PET/CT. Disease progression (red column) was defined also in case of SULpeak increase less than 30% but increase > 75% of total lesion glycolysis (TLG) or in case of appearance of new lesions

Back to article page